松弛素家族肽受体1（RXFP1）激动剂作为心力衰竭的潜在治疗方法。
The Relaxin Family Peptide Receptor 1 (RXFP1) Agonists as Potential Treatment for Heart Failure.
作者信息
Abdel-Magid Ahmed F
机构信息
Independent Consultant, 1383 Jasper Drive, Ambler, Pennsylvania 19002, United States.
出版信息
ACS Med Chem Lett. 2025 May 23;16(6):955-958. doi: 10.1021/acsmedchemlett.5c00273. eCollection 2025 Jun 12.
Abstract
The invention in this patent application relates to bicyclo[2.2.1]-heptane derivatives represented herein by formula 1. The compounds of formula 1 are relaxin family peptide receptor 1 (RXFP1) agonists and may provide treatments for heart failure, fibrotic diseases, and related diseases such as lung, kidney, and hepatic diseases.
摘要
本专利申请中的发明涉及本文中式1所示的双环[2.2.1]庚烷衍生物。式1的化合物是松弛素家族肽受体1（RXFP1）激动剂，可用于治疗心力衰竭、纤维化疾病以及相关疾病，如肺部、肾脏和肝脏疾病。
相似文献
1
The Relaxin Family Peptide Receptor 1 (RXFP1) Agonists as Potential Treatment for Heart Failure.
ACS Med Chem Lett. 2025 May 23;16(6):955-958. doi: 10.1021/acsmedchemlett.5c00273. eCollection 2025 Jun 12.
2
Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Aug 22;15(9):1424-1426. doi: 10.1021/acsmedchemlett.4c00392. eCollection 2024 Sep 12.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
AMP-Activated Protein Kinase Activators as Therapeutic Targets To Treat Heart Failure and Diseases That Can Benefit from Improved Muscular Performance.
ACS Med Chem Lett. 2025 Jan 28;16(2):207-209. doi: 10.1021/acsmedchemlett.5c00025. eCollection 2025 Feb 13.
5
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
7
Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases.
ACS Med Chem Lett. 2024 Aug 23;15(9):1421-1423. doi: 10.1021/acsmedchemlett.4c00393. eCollection 2024 Sep 12.
8
Upcoming drug targets for kidney protective effects in chronic kidney disease.
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i47-i58. doi: 10.1093/ndt/gfae216.
9
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
10
The Use of Salt-Inducible Kinases (SIKs) Inhibitors as an Emerging Treatment for Inflammatory, Allergic, Autoimmune, Cancer, and Metabolic Diseases.
ACS Med Chem Lett. 2025 May 20;16(6):952-954. doi: 10.1021/acsmedchemlett.5c00274. eCollection 2025 Jun 12.
本文引用的文献
1
Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives.
Clin Res Cardiol. 2024 Aug;113(8):1137-1150. doi: 10.1007/s00392-023-02305-1. Epub 2023 Sep 18.
2
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.
J Pers Med. 2022 Jun 21;12(7):1021. doi: 10.3390/jpm12071021.
3
The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.
Mol Genet Genomic Med. 2020 Apr;8(4):e1194. doi: 10.1002/mgg3.1194. Epub 2020 Feb 26.
4
Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases.
Pharmacol Ther. 2018 Jul;187:61-70. doi: 10.1016/j.pharmthera.2018.02.004. Epub 2018 Feb 12.
5
The human insulin superfamily of polypeptide hormones.
Vitam Horm. 2009;80:1-31. doi: 10.1016/S0083-6729(08)00601-8.
Zotero 插件